These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 19409693)

  • 1. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia.
    Porst H; McVary KT; Montorsi F; Sutherland P; Elion-Mboussa A; Wolka AM; Viktrup L
    Eur Urol; 2009 Oct; 56(4):727-35. PubMed ID: 19409693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
    Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L
    J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial comment on: Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia.
    Volpe A
    Eur Urol; 2009 Oct; 56(4):735-6. PubMed ID: 19409694
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction.
    Broderick GA; Brock GB; Roehrborn CG; Watts SD; Elion-Mboussa A; Viktrup L
    Urology; 2010 Jun; 75(6):1452-8. PubMed ID: 20163842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
    Brock G; Broderick G; Roehrborn CG; Xu L; Wong D; Viktrup L
    BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    McVary KT; Roehrborn CG; Kaminetsky JC; Auerbach SM; Wachs B; Young JM; Esler A; Sides GD; Denes BS
    J Urol; 2007 Apr; 177(4):1401-7. PubMed ID: 17382741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
    Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
    Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
    Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S
    J Urol; 2010 Mar; 183(3):1092-7. PubMed ID: 20092847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of tadalafil 5 mg once daily in the treatment of men with lower urinary tract symptoms suggestive to benign prostatic hyperplasia with or without erectile dysfunction: results from naturalistic observational TadaLutsEd study.
    Bechara A; Casabe A; Rodriguez Baigorri G; Cobreros C
    J Sex Med; 2014 Feb; 11(2):498-505. PubMed ID: 24224728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies.
    Brock GB; McVary KT; Roehrborn CG; Watts S; Ni X; Viktrup L; Wong DG; Donatucci C
    J Urol; 2014 Feb; 191(2):405-11. PubMed ID: 24096120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study.
    Egerdie RB; Auerbach S; Roehrborn CG; Costa P; Garza MS; Esler AL; Wong DG; Secrest RJ
    J Sex Med; 2012 Jan; 9(1):271-81. PubMed ID: 21981682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment.
    Roehrborn CG; Kaminetsky JC; Auerbach SM; Montelongo RM; Elion-Mboussa A; Viktrup L
    BJU Int; 2010 Feb; 105(4):502-7. PubMed ID: 19732051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tamsulosin-controlled, 12-week double-blind study.
    Giuliano F; Oelke M; Jungwirth A; Hatzimouratidis K; Watts S; Cox D; Viktrup L
    J Sex Med; 2013 Mar; 10(3):857-65. PubMed ID: 23346990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride.
    Glina S; Roehrborn CG; Esen A; Plekhanov A; Sorsaburu S; Henneges C; Büttner H; Viktrup L
    J Sex Med; 2015 Jan; 12(1):129-38. PubMed ID: 25353053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Stief CG; Porst H; Neuser D; Beneke M; Ulbrich E
    Eur Urol; 2008 Jun; 53(6):1236-44. PubMed ID: 18281145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tadalafil - a therapeutic option in the management of BPH-LUTS.
    Carson CC; Rosenberg M; Kissel J; Wong DG
    Int J Clin Pract; 2014 Jan; 68(1):94-103. PubMed ID: 24341303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?
    Roumeguère T; Zouaoui Boudjeltia K; Hauzeur C; Schulman C; Vanhaeverbeek M; Wespes E
    BJU Int; 2009 Aug; 104(4):511-7. PubMed ID: 19239452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study.
    Bechara A; Romano S; Casabé A; Haime S; Dedola P; Hernández C; Rey H
    J Sex Med; 2008 Sep; 5(9):2170-8. PubMed ID: 18638006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study.
    Donatucci CF; Brock GB; Goldfischer ER; Pommerville PJ; Elion-Mboussa A; Kissel JD; Viktrup L
    BJU Int; 2011 Apr; 107(7):1110-6. PubMed ID: 21244606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12 weeks of treatment.
    Roehrborn CG; Egan KB; Miner MM; Ni X; Wong DG; Rosen RC
    BJU Int; 2016 Jul; 118(1):153-60. PubMed ID: 26765325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.